Acutus Goes Public To Compete With Established Electrophysiology Players
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
You may also be interested in...
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.